Back to Search
WESLEY DOUGALL, MD
MD
Anesthesiology Physician
NPI: 1396397097IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
57.247299(OH)
Anesthesiology PhysicianPrimary
Anesthesiology
Code: 207L00000X
35.144409(OH)MD61407162(WA)
Education
OTHER
Class of 2009
Research & Publications (20)
RANKL signaling in bone physiology and cancer.
PMID 18685382·Curr Opin Support Palliat Care·2007
6-review
[Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases].
PMID 16582514·Clin Calcium·2006
6-review
The RANK/RANKL/OPG triad in cancer-induced bone diseases.
PMID 17180711·Cancer Metastasis Rev·2006
6-review
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
PMID 19016581·J Bone Miner Res·2009
7-preclinical
Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
PMID 18929692·Bone·2009
7-preclinical
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
PMID 18606716·Mol Cancer Ther·2008
7-preclinical
RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
PMID 17964729·Cancer Treat Rev·2008
6-review
RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.
PMID 18324676·Prostate·2008
7-preclinical
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
PMID 18064531·Clin Exp Metastasis·2008
7-preclinical
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
PMID 18008334·Prostate·2008
7-preclinical
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
PMID 17579046·J Immunol·2007
4-observational
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.
PMID 17541032·Mol Cancer Ther·2007
7-preclinical
RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini.
PMID 17145767·Mol Cell Biol·2007
7-preclinical
Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.
PMID 16995812·J Bone Miner Res·2006
7-preclinical
Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.
PMID 16912914·Clin Exp Metastasis·2006
7-preclinical
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
PMID 16005175·J Orthop Res·2005
7-preclinical
Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
PMID 15485831·J Biol Chem·2004
7-preclinical
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
PMID 14633717·Cancer Res·2003
7-preclinical
The surface antigen CD45R identifies a population of estrogen-regulated murine marrow cells that contain osteoclast precursors.
PMID 12810165·Bone·2003
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4800 SAND POINT WAY NE
SEATTLE, WA 98105 - Phone
- (206) 466-8239
Quick Facts
- NPI
- 1396397097
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 17
- Publications
- 20
Are you this provider?
Claim Your Profile